astrazeneca_building_white

AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes

pharmafile | August 30, 2018 | News story | Research and Development, Sales and Marketing |  AstraZeneca, Bydureon, EU, Europe, diabetes, pharma, type 2 diabetes 

AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for the treatment of type 2 diabetes, an expansion of the existing authorisation for Bydureon.

This new formulation delivers via a once-weekly injection an improved single dose, requiring no titration and can be used alongside other glucose-lowering treatments such as basal insulin.

The EC’s decision was based on data derived from two clinical trials, wherein it reduced HbA1c levels by 1.4% after 28 weeks of use compared to Byetta (exenatide), another AZ therapy delivered twice-daily, which demonstrated reductions of just 1% in comparison. Additionally, Bydureon BCise reduced weight on average by 1.5kg as a monotherapy and 1.9kg when combined with oral antidiabetic medicines.  

Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolism, Global Medicines Development at AstraZeneca,explained: “Building on the already well-established efficacy and safety profile of once-weekly Bydureon, today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.”

Advertisement

Matt Fellows

Related Content

Phoenix Labs acquires Kent Pharma

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content